Lilly deal could set the bar for disclosures

Share this content:
Eli Lilly & Co.'s $62 million settlement with 32 states and the District of Columbia over off-label Zyprexa marketing comes with a stringent agreement requiring, among other things, that the company furnish those state attorney generals with a list of all healthcare professionals paid more than $100 for promotional speaking and consulting in the US. 

That's well below the $500-and-up threshold for public disclosure laid out in a transparency policy announced last month, and could set the bar for reporting requirements in future agreements with states. 

The agreement includes provisions governing promotional activities, dissemination of medical information, CME grants, payments to consultants and speakers, sampling and clinical research, and stipulates areas and activities which are off limits to sales and marketing teams.

Arnold Friede, counsel at law firm McDermott, Will & Emery's Washington, DC, office, said the settlement is notable for how the states are asserting themselves in areas traditionally the province of FDA. “It's further evidence that state AGs are stepping into the shoes evacuated by FDA,” said Friede. 

“Until FDA really starts aggressively policing the market to their satisfaction, they are going to do it,” he continued. “The real question is what are the unintended consequences of this reporting obligation—will doctors shy away from entering into legitimate and appropriate relationships with pharma companies in fear of being outed and people just assuming that they're on the take?” 

The agreement, binding through 2014, prohibits Lilly from promoting off-label uses of Zyprexa and bars sales and marketing teams from: developing the medical content of, suggesting topics for or distributing medical references or medical letters regarding the drug; distributing reprints of journal articles discussing off-label uses of the drug; initiating, coordinating or implementing grant applications on behalf of healthcare professionals; selecting grantees or CME-funded speakers; measuring or tracking in any way the impact of grants or speaking fees on participating healthcare professionals' prescribing habits, practices or patterns; approving grant requests regarding Zyprexa or distributing Zyprexa samples to practices inconsistent with the labeling (which covers emergency medicine, family practice, general practice, internal medicine and psychiatry).

The provision regarding sampling is particularly interesting in light of the increasing scrutiny on samples. 
“Maybe this is the beginning of a bigger fight about samples,” said Friede. 

The company is required to register on a public website all clinical trials on the drug from Phase 2 and up initiated since July 2005 and all those completed since July 2004. It must disclose grants for Zyprexa consistent with its current disclosure policy. And it must provide each signatory AG a list of all healthcare professionals paid taxable income of more than $100 for promotional speaking or consulting performed in the US. 

In a statement, Lilly SVP and general counsel Robert Armitage said: “Lilly's policies and practices already mirror most of the provisions included in the proposed consent decrees. This resolution reflects our commitment to continually build on a foundation of compliance, accuracy and transparency.”

Lilly admitted no wrongdoing in the settlement—the costliest yet for a drug company in a state consumer protection case, topping Merck's $58 million Vioxx settlement. Lilly was accused of marketing the drug for off-label uses. 

Share this content:
Scroll down to see the next article